Ab Initio Biotherapeutics Overview
- Founded
- 2015
- Status
- Acquired/Merged
- Latest Deal Type
- M&A
- Latest Deal Amount
- $12M
Ab Initio Biotherapeutics General Information
Description
Developer of protein engineering platform designed for the discovery of therapeutic antibodies against difficult-to-access cellular targets. The company's platform allows for targeting multi-transmembrane and facilitates antibody generation relevant to a wide array of therapeutic indications including neurological, cardiovascular, endocrine and gastrointestinal disorders, enabling doctors to optimize the solubility and stability of drugs.
Contact Information
Website
Ownership Status
Acquired/Merged
Financing Status
Formerly Accelerator/Incubator backed
Primary Office
- 280 Utah Avenue
- South San Francisco, CA 94080
- United States
Ab Initio Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 23-Jul-2019 | $12M | 000 | 0000 | Completed | Generating Revenue |
| 3. Corporate | 13-Dec-2016 | 000 | Completed | Startup | ||
| 2. Angel (individual) | $2M | $2M | Completed | Startup | ||
| 1. Accelerator/Incubator | 03-Mar-2015 | Completed | Startup |
Ab Initio Biotherapeutics Executive Team (6)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Robert Booth Ph.D | Co-Founder & Executive Chairman |
Ab Initio Biotherapeutics Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Robert Booth Ph.D | Self | Co-Founder & Executive Chairman | 000 0000 |
Ab Initio Biotherapeutics Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| JLABS | Accelerator/Incubator | 000 0000 | 000000 0 | ||
| Pfizer | Corporation | Minority | 000 0000 | 000000 0 | |
| Polaris Partners | Venture Capital | Minority | 000 0000 | 000000 0 |